Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cormedix (DE:19KA)
STUTTGART:19KA
Cormedix (19KA) Stock Price & Analysis
1 Followers
19KA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.66 - €5.85
Previous Close€4.82
Volume0.00
Average Volume (3M)642.00
Market Cap
€279.77M
Enterprise Value€209.11M
Total Cash (Recent Filing)$76.03M
Total Debt (Recent Filing)$668.00K
Price to Earnings (P/E)N/A
Beta1.34
Next Earnings
May 13, 2024EPS Estimate
-€0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume642
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.54
Forecast
1Y Price Target
€11.83Price Target Upside145.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cormedix News
Bulls Say, Bears Say
Bulls Say
Commercial Strategy And LaunchCorMedix is gearing up for a strategic commercial launch of DefenCath, targeting both inpatient and outpatient settings, with clear timelines and confirmed interest from healthcare providers.
Pricing And ReimbursementWith DefenCath's list price set at $249.99 per 3mL vial and eligibility for reimbursement, CorMedix may see a favorable financial impact, enhancing the stock's attractiveness.
Product Approval And Market PotentialDefenCath received FDA approval and is recognized for its potential to significantly reduce catheter-related bloodstream infections in hemodialysis patients, which may lead to increased demand and market penetration.
Bears Say
Analyst ExpectationsAnalyst adjusts the price target to $10 from $12 to reflect a slower initial sales ramp.
Regulatory ChallengesCMS has not yet made a determination or provided a timeline for a final decision on the J-Code request or reimbursement path.
Revenue ImpactCRMD does not expect any meaningful DefenCath revenues until a reimbursement process is established.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors
19KA FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was €2.66 and its highest was €5.85 in the past 12 months.
What is Cormedix’s market cap?
Currently, no data Available
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is May 13, 2024 which is in 17 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Mar 12, 2024. The company reported -€0.244 earnings per share for the quarter, missing the consensus estimate of -€0.188 by -€0.055.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is -€0.26.
How many shares outstanding does Cormedix have?
Currently, no data Available
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of -€0.244 in its last earnings report, missing expectations of -€0.188. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Cormedix?
Among the largest hedge funds holding Cormedix’s share is Elliott Investment Management LP. It holds Cormedix’s shares valued at 6M.
---
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.83 (145.42% Upside)
€11.83 (145.42% Upside)
Blogger Sentiment
Bullish
DE:19KA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $50.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.43%
12-Months-Change
Fundamentals
Return on Equity
-74.02%
Trailing 12-Months
Asset Growth
32.27%
Trailing 12-Months
Company Description
Cormedix
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
---
19KA Earnings Call
Q4 2024
0:00 / 0:00
---
19KA Stock 12 Months Forecast
Average Price Target
€11.83
▲(145.42% Upside)
Technical Analysis
Cormedix
―
Corbus Pharmaceuticals
―
Palatin Technologies
―
Oragenics
―
Kala Pharmaceuticals
―
Best Analysts Covering 19KA
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+10.46%
reiterated a buy rating 17 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +10.46% per trade.
---